Plasminogen_deficiency_type_I

Hypoplasminogenemia

Hypoplasminogenemia

Medical condition

Hypoplasminogenemia, also known as plasminogen deficiency type 1, is a genetic disorder characterized by a lack of the protein plasminogen, which is responsible for the ability of the body to break down fibrin clots.[1] Plasminogen deficiency leads to an accumulation of fibrin, causing the development of growths (lesions) that can impair normal tissue and organ function and may lead to blindness when these lesions affect the eyes.[1]

Quick Facts Other names ...

It is caused by mutations in the PLG gene.[2]

Treatment

Plasminogen, human-tvmh (Ryplazim) was approved for medical use in the United States in June 2021.[1] It is the first therapy for hypoplasminogenemia approved by the U.S. Food and Drug Administration (FDA).[1]

References

  1. [1]
    "FDA Approves First Treatment for Patients with Plasminogen Deficiency, a Rare Genetic Disorder". U.S. Food and Drug Administration (FDA) (Press release). 4 June 2021. Retrieved 5 June 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  2. [2]
    "Congenital plasminogen deficiency". MedlinePlus Genetics. Retrieved 5 June 2021.


Stub icon

This genetic disorder article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Plasminogen_deficiency_type_I, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.